{"organizations": [], "uuid": "8b6faba6abc752f01a5d999105a3298a01dfa833", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-nemaura-announces-positive-results/brief-nemaura-announces-positive-results-for-its-sugarbeat-european-clinical-program-idUSFWN1PQ1EJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Nemaura Announces Positive Results For Its Sugarbeat European Clinical Program", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T20:34:00.000+02:00", "replies_count": 0, "uuid": "8b6faba6abc752f01a5d999105a3298a01dfa833"}, "author": "", "url": "https://www.reuters.com/article/brief-nemaura-announces-positive-results/brief-nemaura-announces-positive-results-for-its-sugarbeat-european-clinical-program-idUSFWN1PQ1EJ", "ord_in_thread": 0, "title": "BRIEF-Nemaura Announces Positive Results For Its Sugarbeat European Clinical Program", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "January 31, 2018 / 6:34 PM / in 24 minutes BRIEF-Nemaura Announces Positive Results For Its Sugarbeat European Clinical Program Reuters Staff \nJan 31 (Reuters) - Nemaura Medical Inc: \n* NEMAURA ANNOUNCES POSITIVE RESULTS FOR ITS SUGARBEATÂ® EUROPEAN CLINICAL PROGRAM \n* NEMAURA MEDICAL - SUGARBEAT IS EXPECTED TO LAUNCH IN UK, FOLLOWED BY OTHER TERRITORIES UPON ACHIEVING CE APPROVAL, WHICH IS ANTICIPATED IN COMING MONTHS \n* NEMAURA MEDICAL INC - ADDITIONAL CLINICAL STUDIES ARE PLANNED FOR SUGARBEAT FOR FDA APPROVAL IN U.S. \n* NEMAURA MEDICAL - ADDITIONAL CLINICAL STUDIES ARE PLANNED FOR SUGARBEAT FOR FDA APPROVAL IN U.S., AND FOR USE OF SUGARBEAT IN CRITICAL CARE SETTINGS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-31T20:34:00.000+02:00", "crawled": "2018-01-31T20:54:48.000+02:00", "highlightTitle": ""}